News
SEEL
0.2100
-7.89%
-0.0180
Weekly Report: what happened at SEEL last week (0902-0906)?
Weekly Report · 21h ago
Weekly Report: what happened at SEEL last week (0826-0830)?
Weekly Report · 09/02 12:33
Weekly Report: what happened at SEEL last week (0819-0823)?
Weekly Report · 08/26 12:30
Trials for psychedelic drug candidate for PTSD under scrutiny by FDA - report
Seeking Alpha · 08/23 22:34
Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Benzinga · 08/19 17:37
Weekly Report: what happened at SEEL last week (0812-0816)?
Weekly Report · 08/19 12:10
Earnings week ahead: Zoom, Lowe's, Target, Baidu, XPeng, Zim Integrated and more
Seeking Alpha · 08/18 12:03
SEEL Stock Earnings: Seelos Therapeutics Beats Revenue for Q2 2024
Investorplace · 08/17 01:53
Seelos Therapeutics files to sell 1.95M shares of common stock for holders
Seeking Alpha · 08/16 20:13
US Stocks Edge Lower; Applied Materials Earnings Top Views
Benzinga · 08/16 13:56
Why Greenland Technologies Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket
Benzinga · 08/16 10:55
Lykos laying off 75% of workforce following FDA rejection of psychedelic drug for PTSD
Seeking Alpha · 08/15 19:02
Seelos: Q2 Earnings Snapshot
Barchart · 08/15 04:03
Form 10-Q for Seelos Therapeutics, Inc. for the quarterly period ended June 30, 2024
Press release · 08/14 21:19
Medical journal retracts three articles related to MDMA for PTSD
Seeking Alpha · 08/12 15:50
Weekly Report: what happened at SEEL last week (0805-0809)?
Weekly Report · 08/12 12:13
Psychedelic drug developers face setback as ecstasy-based drug rejected by FDA
Seeking Alpha · 08/09 22:04
Weekly Report: what happened at SEEL last week (0729-0802)?
Weekly Report · 08/05 12:29
EXCLUSIVE: Legal Magic Mushroom Products Will Be Sold In Jamaica As Psilocybin Products Hit Pharmacy Shelves
Benzinga · 07/31 12:00
Weekly Report: what happened at SEEL last week (0722-0726)?
Weekly Report · 07/29 12:14
More
Webull provides a variety of real-time SEEL stock news. You can receive the latest news about Seelos Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About SEEL
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of products that address significant unmet needs in Central Nervous System (CNS) disorders and other rare disorders. The Company operates under one segment which develops pharmaceutical products. The Company's programs include SLS-002 for the potential treatment of acute suicidal ideation and behavior (ASIB) in patients with major depressive disorder (MDD) and SLS-005 for the potential treatment of amyotrophic lateral sclerosis (ALS) and spinocerebellar ataxia (SCA). SLS-002 is intranasal racemic ketamine with two investigational new drug applications (INDs). SLS-005 is used for the potential treatment of Sanfilippo Syndrome. SLS-005 is IV trehalose, a protein stabilizer that crosses the blood-brain barrier and activates autophagy and the lysosomal pathway. The Company's ongoing preclinical programs include SLS-004, SLS-006, and SLS-007.